Announcement of Zhaoyan Pharmaceutical's response to the Shanghai Stock Exchange's letter on the information disclosure supervision of the company's 2023 annual report

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.